Takeda, Resilience enter development deal for plasma meds

Feb. 16, 2022

Tech-focused manufacturing company National Resilience has signed a development agreement with Takeda Pharmaceutical's plasma-derived therapies business unit, the companies announced earlier this week.

The terms of the agreement state that Resilience will support the development and manufacturing of multiple products in Takeda’s plasma-derived medicines portfolio, according to Resilience. The development will be run out of Resilience’s facility in Mississauga, Ontario, which spans over three acres.

Massachusetts-based Resilience is a newcomer to the pharma industry, launching onto the scene in November 2020. Resilience’s mission is to build 'the world's most advanced biopharmaceutical manufacturing ecosystem.' The company aims to use the latest technologies to improve the manufacturing and distribution process.

Takeda, based out of Japan, is the largest drug manufacturer in Asia. The pharma giant is known for its extensive pipeline and development of therapies like Nesina, a treatment for high blood glucose in patients with Type 2 diabetes.

“We are delighted to form this strategic collaboration with Resilience, leveraging their expertise in both plasma therapy development and manufacturing to complement our current infrastructure and capabilities,” said Andreas Liebminger, head of pharmaceutical sciences and devices for the plasma-derived therapies business unit at Takeda. 

Despite its recent launch, Resilience has set about making a splash in the pharma scene. In September, Moderna and Resilience signed an agreement for Resilience to produce mRNA for Moderna’s COVID-19 vaccine. The mRNA will also be produced at Resilience’s factory in Ontario, for distribution worldwide.